Last reviewed · How we verify
NCT04698694: EPIC
ElectroPoration In a Clinical Setting
NA trial testing Electroporation with voltage amplitude of 40 V (corresponding to an electric field strength of 100 V/cm) in Tolerance in 24 participants. Completed in 21 December 2020.
14 December 2020
Quick facts
| Lead sponsor | University of Milano Bicocca |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 9 December 2020 |
| Primary completion | 14 December 2020 |
| Estimated completion | 21 December 2020 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Electroporation with voltage amplitude of 40 V (corresponding to an electric field strength of 100 V/cm)
- Electroporation with voltage amplitude of 60 V (corresponding to an electric field strength of 150 V/cm)
Conditions studied
- Tolerance — all drugs for Tolerance →
Sponsor
University of Milano Bicocca
Who can join
Adults 18 Months to 55, any sex, with Tolerance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-blind, single-center, randomized, study in healthy subjects in which the volunteer patients will remain blind with respect to the voltage strength received.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04698694
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tolerance
Currently open trials in the same condition.
- NCT06189170 — Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients · EARLY_PHASE1 · recruiting
- NCT05644717 — Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD · Phase 4 · recruiting
- NCT05022420 — SAfety and TOlerance of the Biopsies in Auto-immune Rare dIseases · recruiting
- NCT06286488 — Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza · Phase 4 · active not recruiting
Other University of Milano Bicocca trials
Trials by the same sponsor.
- NCT07257705 — Pilot Trial of a Clinical Decision-Support App for Managing Emergencies Among Clinicians in a Rural Ugandan Hospital · NA · completed
- NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
- NCT07407608 — ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0 · recruiting
- NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
- NCT07424066 — Non-invasive Vibratory Stimulation of the Knee Muscles for the Improvement of the Somatosensory Input and Motor Performa · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04698694 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Milano Bicocca
- Last refreshed: 21 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04698694.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing